Daniel Lin
Overview
Explore the profile of Daniel Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
2078
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bloom M, Podder S, Dang H, Lin D
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076561
Over the past several years, the therapeutic landscape for patients with advanced, unresectable, or metastatic hepatocellular carcinoma has been transformed by the incorporation of checkpoint inhibitor immunotherapy into the treatment...
2.
Shaikh A, Lin D
J Gastrointest Oncol
. 2024 Nov;
15(5):2343-2348.
PMID: 39554561
No abstract available.
3.
Chahine S, Alkhatib K, Arakelyan G, Buxton C, Giannarini G, Hamilton R, et al.
Eur Urol Focus
. 2024 Aug;
PMID: 39147634
Background And Objective: There are limited data on the prevalence and management of testicular germ cell tumor (TGCT) cases presenting with venous tumor thrombus (VTT). Our objectives were to describe...
4.
Poiset S, Shah S, Cappelli L, Anne P, Mooney K, Werner-Wasik M, et al.
Radiat Oncol
. 2024 May;
19(1):65.
PMID: 38812040
Background: Local treatment options for locally recurrent pancreatic adenocarcinoma (LR-PAC) are limited, with median survival time (MST) of 9-13 months (mos) following recurrence. MRI-guided stereotactic body radiation therapy (MRgSBRT) provides...
5.
Majeed A, Alaparthi S, Halegoua-DeMarzio D, Eberle-Singh J, Jiang W, Anne P, et al.
World J Oncol
. 2024 May;
15(3):511-520.
PMID: 38751709
Hepatocellular carcinoma (HCC) is often diagnosed at a late stage and frequently recurs despite curative intervention, leading to poor survival outcomes. Frontline systemic therapies include combination immunotherapy regimens and tyrosine...
6.
Lin D, Tan R, Teigland C, Hernandez S, Kim S, Kilgore K
Future Oncol
. 2024 Apr;
20(24):1765-1777.
PMID: 38639552
Evaluate the association of race/ethnicity and socioeconomic position (SEP) on emergency department (ED) visits for patients with hepatocellular carcinoma (HCC), which may reflect access to and quality of cancer care....
7.
Baker H, Cuomo B, Femia C, Lin D, Stobbie C, McLean B, et al.
Aust Occup Ther J
. 2024 Jan;
71(2):279-290.
PMID: 38221771
Introduction: Transitioning into the role of a mother encompasses many physical and psychosocial changes, affecting the way a woman may function. Maternal health is an emerging area of practice for...
8.
Li D, Loriot Y, Burgoyne A, Cleary J, Santoro A, Lin D, et al.
EClinicalMedicine
. 2024 Jan;
67:102376.
PMID: 38204489
Background: Cabozantinib is approved for previously treated advanced hepatocellular carcinoma (aHCC) and has been investigated in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ). Atezolizumab plus bevacizumab is approved for...
9.
Lin D, Lechermann L, Huestis M, Marik J, Sap J
Angew Chem Int Ed Engl
. 2023 Dec;
63(14):e202317136.
PMID: 38135665
This review discusses recent advances in light-driven radiochemistry for three key isotopes: fluorine-18, carbon-11, and zirconium-89, and their applications in positron emission tomography (PET). In the case of fluorine-18, the...
10.
Manzar G, Alam M, Lynn E, Karpinets T, Harris T, Lo D, et al.
Brachytherapy
. 2023 Dec;
23(2):123-135.
PMID: 38129211
Background: Chemoradiation (CRT) may modulate the immune milieu as an in-situ vaccine. Rapid dose delivery of brachytherapy has unclear impact on T-cell repertoires. HPV-associated cancers express viral oncoproteins E6/E7, which...